350 related articles for article (PubMed ID: 26382932)
1. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
2. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort.
Charnaya O; Tuchman S; Moudgil A
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29356221
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies.
Parajuli S; Alagusundaramoorthy S; Aziz F; Garg N; Redfield RR; Sollinger H; Kaufman D; Djamali A; Odorico J; Mandelbrot D
Transplantation; 2019 Feb; 103(2):435-440. PubMed ID: 29994978
[TBL] [Abstract][Full Text] [Related]
4. The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomes.
Loucks-DeVos JM; Eagar TN; Gaber AO; Patel SJ; Teeter LD; Graviss EA; Knight RJ
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28582797
[TBL] [Abstract][Full Text] [Related]
5. Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients.
Engen RM; Park GE; Schumacher CS; Gimferrer I; Warner P; Finn LS; Weiss NS; Smith JM
Transplantation; 2018 Dec; 102(12):2072-2079. PubMed ID: 29863579
[TBL] [Abstract][Full Text] [Related]
6. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
[TBL] [Abstract][Full Text] [Related]
8. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
9. Role of de novo donor-specific anti-HLA antibodies in kidney graft failure: A case-control study.
Castro A; Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
HLA; 2017 Nov; 90(5):267-275. PubMed ID: 28776960
[TBL] [Abstract][Full Text] [Related]
10. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
[TBL] [Abstract][Full Text] [Related]
11. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
15. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients.
Hirai T; Furusawa M; Omoto K; Ishida H; Tanabe K
Transplantation; 2014 Aug; 98(4):443-50. PubMed ID: 24717219
[TBL] [Abstract][Full Text] [Related]
16. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
[TBL] [Abstract][Full Text] [Related]
17. Utility of protocol kidney biopsies for de novo donor-specific antibodies.
Parajuli S; Reville PK; Ellis TM; Djamali A; Mandelbrot DA
Am J Transplant; 2017 Dec; 17(12):3210-3218. PubMed ID: 28805293
[TBL] [Abstract][Full Text] [Related]
18. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
[TBL] [Abstract][Full Text] [Related]
19. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
20. De novo donor-specific antibody following BK nephropathy: The incidence and association with antibody-mediated rejection.
Cheungpasitporn W; Kremers WK; Lorenz E; Amer H; Cosio FG; Stegall MD; Gandhi MJ; Schinstock CA
Clin Transplant; 2018 Mar; 32(3):e13194. PubMed ID: 29315820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
